Return to program book search
From Bench to Bedside: Important Clinical Advances
Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
Saturday, August 18
8:00 AM - 9:30 AM
Oscar Colegio, MD, PhD, FAAD
Following this course, the attendee should be able to:
- Describe molecular pathways recently discovered to be effective targets for treating melanoma, basal cell carcinoma and dermatofibrosarcoma protuberans.
- Summarize the efficacy of recently approved therapies or therapies currently in trials for the treatment of skin cancers.
Systemic and topical molecularly targeted therapies are emerging as a rational approach to the management of skin cancers. In this session, the rationale behind and effectiveness of new molecules used in the treatment of melanoma, basal cell carcinoma, dermatofibrosarcoma protuberans and Kaposi’s sarcoma will be reviewed. This session is designed for a broad audience, from practicing dermatologists to basic scientists.